Le Lézard2d
Enhancing Antibody Therapeutics Through Precision Glycoengineering, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about advancements in cell line development and glycoengineering. Attendees will gain insights into how precise glycan modulation boosts antibody-dependent cell-mediated ...
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
Medscape6d
Immunotherapy in Pediatric Malignancies
or bring a T cell adjacent to the tumor (e.g., bispecific mAb). ADCC: Antibody-dependent cellular cytotoxicity; mAb: Monoclonal antibody.
Le Lézard4d
First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab
Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today announced that the first subject ...
Morningstar6d
Cantargia’s TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited
About nadunolimab (CAN04) The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract ...
Finanznachrichten4d
First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab
LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA) Open label study in forty AML and MDS patients Study financed by the US Department of Defense Cantargia (Cantargia AB; Nasdaq ...
Yahoo Finance5d
iTeos Therapeutics, Inc. (ITOS)
After hours: March 11 at 6:08:44 PM EDT Loading Chart for ITOS ...